Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Core Insights - Natera had a strong performance in Q4 2025, exceeding internal expectations in both volumes and revenues [3] - The company reported a significant increase in gross margins, with organic gross margins reaching approximately 64% and 67% when including true-ups [3] - The growth across the portfolio was robust, with the Signatera product achieving record unit sales and notable clinical trial data contributing to its success [4] Financial Performance - Q4 2025 finished with strong revenue growth, surpassing consensus estimates [2] - Gross margin improved by approximately 240 basis points, indicating strong operational efficiency [3] - The overall performance in 2025 was characterized by significant growth across various product lines [4] Strategic Focus - Key priorities for 2026 include maintaining growth momentum and leveraging positive clinical trial outcomes to drive further product adoption [2][4] - Continued emphasis on enhancing gross margins and operational performance is expected to be a focus area moving forward [3]